We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+42.28%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$142M
AUM Growth
-$5.53M
Cap. Flow
-$27M
Cap. Flow %
-19.04%
Top 10 Hldgs %
77.36%
Holding
36
New
6
Increased
6
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$4.19M
2
STRO icon
Sutro Biopharma
STRO
+$3.65M
3
DRUG
Bright Minds Biosciences
DRUG
+$2.22M
4
TNGX icon
Tango Therapeutics
TNGX
+$2.21M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$2.19M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$19.7M
2
TERN
Terns Pharmaceuticals
TERN
+$5.8M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$4.93M
4
INSM icon
Insmed
INSM
+$4.5M
5
OCUL icon
Ocular Therapeutix
OCUL
+$4.39M

Sector Composition

Rank Sector Weight
1 Healthcare 97.59%

No holdings matched the selected filter criteria.

1 2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Acuta Capital Partners held 36 positions worth $142M, down 3.8% from $147M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Acuta Capital Partners withdrew a net $27M in Q1 2026, closing 9 positions and reducing 13 holdings. Its most notable exit was Cidara Therapeutics, an estimated $19.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Erasca worth $5.74M.

  • Acuta Capital Partners's largest Q1 2026 buy was Erasca: 354,575 shares worth $5.74M.
  • Acuta Capital Partners added most to Sutro Biopharma in Q1 2026, an estimated $3.65M increase.
  • Acuta Capital Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $5.8M.
  • Acuta Capital Partners fully exited Cidara Therapeutics in Q1 2026, selling an estimated $19.7M.
  • Acuta Capital Partners's ten largest holdings make up 77% of its $142M portfolio in Q1 2026.
  • Acuta Capital Partners opened 6 new positions and closed 9 in Q1 2026.
  • Acuta Capital Partners's portfolio value fell 3.8% quarter-over-quarter to $142M.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.